longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

AstraZeneca

AZN

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfileWeekly ReviewWeekly Review
LongbridgeAI

Current ValuationThe current P/E ratio is 24.18, below the reasonable range, cheaper than 88.1% of the time in the past 5 years, and the industry ranks 43/257, the industry Median -1.27.

24.18xP/E
$162.89Stock price
$6.74Earnings per share
24.18xP/E
Stock price$162.89Earnings per share$6.74

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
33.64x
Typical range
27.96x–49.94x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
RHHVFUSROCHE HOLDINGS AG
23.27x--$359.82B
RHHBYUSRoche
22.74x--$351.53B
NVSUSNOVARTIS AG
20.67x1.82%$263.63B
AZNUSAstraZeneca
24.18x--$252.63B
SNYUSSanofi
22.21x20.80%$102.05B
SNYNFUSSanofi
22.64x--$104.04B
CHGCYUSChugai Pharmaceutical
22.44x--$67.59B
MKKGYUSMerck
23.81x--$65.50B
RDYUSDr Reddys Laboratories
27.00x11.22%$9.73B
LGNDUSLigand Pharmac-B
27.82x14.55%$5.49B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.